A frequency-aware sparse vision transformer outperformed comparison models on organ, cardiac, breast, skin and polyp ...
Five participants received SGT-212 in the Phase 1b FALCON trial; initial data are expected in Q1 2027. FDA granted three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results